The sweet and sour of cancer: glycans as novel therapeutic targets

By M. Fuster, J. Esko. Nature Reviews. Cancer, 2005

1,308 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/597fdfff6847ff3f801a87cc7309959caf827354

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. J. Esko

In Molecular Biology

1. J. Esko
2. Phatsapong Yingchoncharoen
3. D. Richardson
4. D. Kalinowski

In Organic Chemistry

1. Phatsapong Yingchoncharoen
2. J. Esko
3. D. Richardson
4. D. Kalinowski

Citations in the corpus

• Heparan sulphate proteoglycans fine-tune mammalian physiology (2007, background): “Tumour HSPGs differ in composition from HSPGs in corresponding normal tissue, which might affect the efficiency of growth-factor stimulation of tumour cell”
• Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “A different type of anionic glycosaminoglycan also exists in the glycocalyx called hyaluronic acid, which does not attach itself to core proteins but to the CD44 receptor (Fuster and Esko, 2005; Reitsma et al., 2007; van Golen et al., 2012).”